These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 7495121

  • 1. Loss of HLA class I expression in prostate cancer: implications for immunotherapy.
    Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL.
    Urology; 1995 Nov; 46(5):681-6; discussion 686-7. PubMed ID: 7495121
    [Abstract] [Full Text] [Related]

  • 2. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.
    Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA.
    Clin Cancer Res; 2000 Jul; 6(7):2794-802. PubMed ID: 10914726
    [Abstract] [Full Text] [Related]

  • 3. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
    Kageshita T, Ishihara T, Campoli M, Ferrone S.
    Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
    [Abstract] [Full Text] [Related]

  • 4. HLA-class I expression in gastric cancer.
    Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T.
    J Surg Oncol; 2008 Jun 01; 97(7):605-8. PubMed ID: 18459158
    [Abstract] [Full Text] [Related]

  • 5. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS.
    Cancer Res; 2000 Dec 15; 60(24):7099-105. PubMed ID: 11156417
    [Abstract] [Full Text] [Related]

  • 6. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
    Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N, Gatter K, Talbot DC, Harris AL, Ganesan TS.
    Clin Cancer Res; 2003 Jan 15; 9(1):84-92. PubMed ID: 12538455
    [Abstract] [Full Text] [Related]

  • 7. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance.
    Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ.
    Gynecol Oncol; 1995 Jun 15; 57(3):366-75. PubMed ID: 7774840
    [Abstract] [Full Text] [Related]

  • 8. Human monoclonal antibodies as a tool for the detection of HLA class I allele-specific expression loss in head-and-neck squamous cell carcinoma and corresponding lymph node metastases.
    Koene G, Mulder A, van der Ven K, Eijsink C, Franke M, Slootweg P, Claas F, Tilanus M.
    Hum Immunol; 2006 Sep 15; 67(9):692-9. PubMed ID: 17002899
    [Abstract] [Full Text] [Related]

  • 9. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss.
    Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT.
    Cancer Res; 1996 Oct 01; 56(19):4387-90. PubMed ID: 8813131
    [Abstract] [Full Text] [Related]

  • 10. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J, Diener PA, Prikler L, Fürstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M.
    Cancer Res; 2000 Oct 01; 60(19):5522-8. PubMed ID: 11034097
    [Abstract] [Full Text] [Related]

  • 11. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage.
    Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S.
    Clin Cancer Res; 2005 Jan 01; 11(1):67-72. PubMed ID: 15671529
    [Abstract] [Full Text] [Related]

  • 12. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition.
    Berghuis D, de Hooge AS, Santos SJ, Horst D, Wiertz EJ, van Eggermond MC, van den Elsen PJ, Taminiau AH, Ottaviano L, Schaefer KL, Dirksen U, Hooijberg E, Mulder A, Melief CJ, Egeler RM, Schilham MW, Jordanova ES, Hogendoorn PC, Lankester AC.
    J Pathol; 2009 Jun 01; 218(2):222-31. PubMed ID: 19274709
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
    Wang JC, Bégin LR, Bérubé NG, Chevalier S, Aprikian AG, Gourdeau H, Chevrette M.
    Clin Cancer Res; 2007 Apr 15; 13(8):2354-61. PubMed ID: 17406028
    [Abstract] [Full Text] [Related]

  • 14. HLA class II antigen presentation by prostate cancer cells.
    Younger AR, Amria S, Jeffrey WA, Mahdy AE, Goldstein OG, Norris JS, Haque A.
    Prostate Cancer Prostatic Dis; 2008 Apr 15; 11(4):334-41. PubMed ID: 17938645
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The expression of HLA class I antigen in prostate cancer in relation to tumor differentiation and patient survival.
    Levin I, Klein T, Kuperman O, Segal S, Shapira J, Gal R, Hart Y, Klein B.
    Cancer Detect Prev; 1994 Apr 15; 18(6):443-5. PubMed ID: 7867017
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas.
    Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M.
    Cancer Res; 1991 Dec 01; 51(23 Pt 1):6372-80. PubMed ID: 1933900
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
    Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC.
    Lab Invest; 1995 Nov 01; 73(5):628-35. PubMed ID: 7474936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.